Quarterly Update: June 2025 Highlights

As the days grow longer and the lab gets sunnier, we’ve been making strides across science, strategy, and summer refreshments. This quarter has brought new partnerships, fresh faces, and more momentum for our platform. Here’s a round-up of what we’ve been up to.

1. Securing Investment to Fuel Growth

We’re excited to announce that we’ve secured new investment from Northstar Ventures and Smartlink Partners. Their support comes at a pivotal time, as we focus on reaching critical commercial milestones and expanding our outreach to leading pharmaceutical companies. This funding will allow us to strengthen our technology offering, grow our business development capabilities, and accelerate our work with partners tackling the toughest challenges in RNA therapeutics.

We're particularly grateful to have investors who not only understand the complexity of what we’re building, but who also share our long-term vision. Their belief in our mission - and in the potential of Nucleic Acid Nanorobotics - is a strong vote of confidence as we move into this next phase of growth.

2. Innovate UK Grant to Advance Molecular Programming

We’re proud to share that we’ve been awarded a new grant from Innovate UK to support the continued development of our molecular programming and computational modelling capabilities. At Nanovery, we’re always striving to deliver novel assays and results faster. A critical part of this is being able to accurately predict how our nanorobots will behave, before they’re built. With stronger in silico modelling, we can now get to optimised assays within the first or second iteration, dramatically reducing turnaround times.

Computational design sits at the heart of our platform, and this grant will help us expand what’s possible. Combined with the arrival of two experienced computational scientists, Karol Kaszuba and Alex Punter, we’re in a stronger position than ever to accelerate assay development across virtually every project we run.

3. Representing Nanovery at SLAS Europe

This June, Ennio represented Nanovery at the SLAS Europe 2025 Conference in Hamburg, which is a leading event for life sciences innovation, automation, and drug discovery technologies. With over 1,000 attendees from across biotech and pharma, the conference provided a valuable platform to engage with scientists and technology developers shaping the future of research tools.

Ennio showcased our work in nucleic acid nanorobotics for bioanalysis, highlighting how Nanovery’s approach is helping to solve long-standing challenges in oligonucleotide detection. From technical conversations to new connections, it was a fantastic opportunity to share our story with a broader European audience.

4. Selected for BioTools Innovator 2025 – A Global Platform for the Future of Biotech Tools

We’re honoured to announce that Nanovery has been selected to join the BioTools Innovator 2025 programme: a highly competitive, industry-backed accelerator dedicated specifically to companies building transformative life science tools and platforms. Backed by a coalition of strategic partners from across the biotech and pharmaceutical industries, the programme is uniquely tailored to support companies like ours that are solving critical unmet needs in research and drug development.

To be chosen from a global pool of applicants is a massive opportunity for us. It validates the work we’ve done so far, and opens new doors as we scale our commercial efforts. The programme kicked off in Mountain View, California, earlier this month, where we joined the 2025 cohort and began building relationships with mentors, investors, and potential customers from across the sector. We’re excited about what’s ahead and grateful for the support and belief from the BioTools Innovator team and their partners.

5. Elderflower Cordial and the Science of Teamwork

Long summer days in the lab call for focus, stamina... and sometimes, a bit of creativity. This month, the team came up with a new way to bring a little refreshment to our workspace: a homemade elderflower cordial, now quietly replacing the standard water cooler.

It’s a small detail, but it speaks to something bigger: our commitment to making the lab a place where ideas flow as freely as conversations. Whether discussing assay optimisation or modelling improvements, these impromptu huddles are often where the best thinking starts.

We take our science seriously, and our mission even more so. Creating a space where people want to be, where they’re supported, engaged, and collaborating, is a big part of why we’re able to move fast and solve hard problems together.

Looking Ahead

As summer progresses, we’re continuing to build, test, and deploy better tools for the RNA therapeutics community. Whether you’re working on ASOs, siRNA, or something even more ambitious - we’d love to hear from you.

Thanks for following our journey. You can always reach us on LinkedIn or contact the team directly!